A 49-year-old womanwith diabetes mellitus developed progressive weakness and atrophy of both thighs rendering her wheelchair-bound within two months. The neurological findings and electrophysiological test results were compatible with diabetic amyotrophy (DA). Immediately after intravenous immunoglobulin (IVIg) therapy (20 gx3 days), she becameable to walk with a cane. After the next course of the therapy, she could walk without assistance. This dramatic effect of IVIg therapy together with the recent observation of vasculitic neuropathy in DAindicates an inflammatory process in this condition, and gives support to this treatment for DA. (Internal Medicine 40: 349-352, 2001) 
Introduction
Diabetic amyotrophy (DA) (diabetic proximal neuropathy, Bruns-Garland syndrome) is an infrequent neuropathic complication of diabetes mellitus (1) . It is characterized by subacute development of symmetrical or asymmetrical weakness and atrophy of the proximal site of the lower limbs, although weaknessof the distal leg muscles is usually minor or absent. Morethan half of DApatients suffer from aching pain in their thighs, but sensory impairment is usually absent (2, 3) . Recent studies have indicated DAmay have an inflammatory basis with microvasculitis (4) (5) (6) . Based on this hypothesis, Krendel et al (6) tried anti-inflammatory treatment including intravenous immunoglobulin (IVIg) therapy in 13 DApatients, all of whomshowedimprovement.Wereport a patient with DAwhich responded well to IVIg therapy.
For editorial comment, see p 273.
Case Report
A 49-year-old womanwas admitted to our hospital in January 1999, because of progressive weakness of both thighs. She had been found to have diabetes mellitus in 1980, but did not begin anti-diabetic treatment until 1994 when her retinopathy became symptomatic. She started hemodialysis because of diabetic nephropathy in December 1997. In October 1998, she noticed that she could not climb stairs or ride her bicycle. She also noticed severe atrophy of both thighs and weight loss (-8 kg), but neither pain nor sensory disturbance. Despite strict blood sugar control since July 1998 (FBS 80-140 mg/dl, GHbAlc 6.2-6.5%), the weakness and atrophy progressed. In December1998, she had to use a cane to walk, and in January 1999, she becameconfined to a wheelchair. She was admitted to our hospital on January 5, 1999. She was not obese (Body Mass Index=22.9), but was hypertensive. Neurological examination revealed marked atrophy of the bilateral thigh and buttock muscles (Fig. 1 ), but normal upper extremity muscles. Manual muscle testing showed 4/5 weakness of both the iliopsoas and tibialis anterior muscles. The level of weakness of the right gluteus medius muscle was 4/5, and the left one was 3/5. Bilateral quadriceps, adductors and hamstrings showed 3/5 weakness, and test of both gluteus medius muscles were 2/5. Pain and touch sensation was intact. Vibration was felt for 12 seconds at the thumb finger, and 6 seconds at bilateral ankles. Tendonreflexes were normal in the upper extremities, but absent in the lower ones. Pathological reflexes were absent.
Laboratory tests (Table 1) showed well controlled diabetes mellitus with renal insufficiency. Serum creatine kinase was normal. The erythrocyte sedimention rate was elevated at 78 mm/h, but the rheumatoid factor and anti-nuclear antibodies were absent. Thethyroid function tests were within normal limits. A cerebrospinal fluid study revealed no abnormality. A nerve conduction study showed a marked decrease in motor conduction velocity (MCV) in the bilateral femoral nerves, and a mild MCVdecrease in the commonperoneal and posterior tibial nerves. The MCVin the upper extremities were within normal limits, and a sensory nerve conduction study revealed mildly decreased velocity in both upper and lower limbs ( Table  2) . Needle electromyography (EMG)showed active neurogenic change in the quadriceps muscles, but did not show any abnormality in the upper limb or distal lower limb muscles (Table  3 ). Brain magnetic resonance imaging (MRI) revealed no abnormality. Spinal MRI showed mild bulging of the vertebral disk at the L2/3 level, but it compressed neither the spinal cord nor any nerve roots. From these clinical and electrophysiological findings, the diagnosis of DAwas made.
Eparestat (aldose reductase inhibitor) and vitamin B 1 2 were given with no benefit. Onemonthlater, she underwent a threeday course of IVIg therapy (400 mg/kg/day). On the following day, she wasable to walk with a cane again. Four weekslater, the same dose of Ig was given. On the third day of the second course, she could walk without assistance. The IVIg therapy was well tolerated without any adverse effect. Follow-up needle EMG (Table 3 ) revealed a small number of polyphasic units without denervation potentials in the quadriceps, which suggested inactivation of proximal neuropathy.
After the discharge on March 16, 1999, the weakness further improved gradually, but muscle atrophy did not change significantly.
On July 19, 1999 (20 weeks after the IVIg therapy), she had an ischemic stroke and was lost to follow-up.
Discussion
The present case showed typical clinical features and laboratory findings of DA, i.e., subacute progressive weakness and atrophy of proximal lower limbs, absence of sensory disturbance, normal CSFstudy, and marked decrease in MCVof the femoral nerve (3). The lack of pathological study could not exclude the possibility of chronic inflammatory demyelinating polyneuropathy (CIDP) completely, but the clinical features and laboratory findings in this case indicated that the possibility was very low. Although MCVand SCVin her lower Table 2 Figure 1. The patient's lower extremities. Muscle wasting of the thighs is evident, but her calves are not atrophic.
MCV:motor nerve conduction velocity, CMAP: compound muscle action potential, SCV:sensory nerve conduction velocity, SNAP: sensory nerve action potential. limbs were mildly decreased, there was no weakness nor atrophy in the distal muscles. Thus, we concluded that her disability was not due to diabetic distal symmetric neuropathy or uremic neuropathy.
Immediately after the IVIg therapy, her DA symptoms improved dramatically. A follow-up needle EMGof the quadriceps muscle performeda few weeksafter the therapy also revealed inactivation of neuropathy. Of course, there is a possibility that the clinical and electrophysiological improvement seen in this case maybe a result of the natural course or placebo effect, because DAis sometimes self-limiting.
The onemonth administration of eparestat without any benefit and almost immediate amelioration of the leg weakness by IVIg therapy, however, seemto support the real effect of the latter tre atment. The cause of DAremains unclear. Two main hypotheses as to its pathogenesis, metabolic and ischemic, have been proposed. Hyperglycemia, which is knownto cause activation of the sorbitol pathway, deficiency of nerve myoinositol, and acceleration of non-enzymatic protein glycosylation, may result in peripheral nerve degeneration (7), while the acute onset and asymmetrical features of DA, and pathologic evidence of ischemic nerve lesions found in autopsied cases (8) , may support the ischemic hypothesis. Recent studies including pathologic observations (4-6) suggest that, at least in some cases, DAhas an inflammatory basis of the nature of ischemia. Said et al (5), who histologically investigated the intermediate cutaneous nerve of the thigh, reported that severe proximal neuropathy was associated with inflammatory cell infiltration, vasculitis and nerve ischemia due to the microangitis. Krendel et al (6) also reported small vessel diseases with chronic perivascular inflammation or arterial occlusion with inflammation in their biopsy series (the specimens were cutaneous branches of the femoral nerves, sural nerves and quadriceps muscles). Although we could not perform a nerve biopsy in our case, the marked and prompt effect of IVIg indicates the presence of a similar inflammatory mechanism.
The natural course of DAis variable, with a gradual, and often incomplete, spontaneous recovery (9, 10). According to recent studies, however, immunomodulating agents may facilitate the recovery. In the study of Krendel et al (6), 13 DApatients were treated with a variety of immunomodulatingagents (IVIg, prednisone, azathioprine and cyclophosphamide). In all of the patients, DA stopped worsening and began to improve. The therapy was well tolerated in all patients except for one who committed suicide. In another study (1 1), all five DApatients, who received a 5-day course of IVIg (0.4 g/kg/day) therapy monthly for 3 months, experienced decreased pain and significant improvement in strength. High-dose IVIg has been applied to autoimmune/inflammatory neurologic diseases ( 1 2). Administered immunoglobulin is considered to inhibit activated complement binding and to prevent the formation of the membranolyticattack complex (13) . It also appears to neutralize certain pathogenic cytokines, downregulate antibody production, block Fc receptors on macrophages, modulate the T cell function and antigen recognition, and enhance remyelination (13, 14) . In diabetic neuropathies, including DA, T cells (CD4 and 8) and B cells associated with an epineural microvasculitis, and T cells (predominantly CD8 cells) infiltration into the endoneurium have been reported (4, ll). Younger et al (ll) also found complement protein (C3d and C5b) deposits in the walls of endoneurial and perineurial blood vessels. Suppression of the lymphocyte function and enhancement of remyelination may play a part of the therapeutic mechanism of IVIg in DA. But the rapid improvement of the clinical symptomsin the present case suggests a morerapidly recoverable mechanism such as normalization of the altered permeability of the endothelium of blood vessels or the endoneurium,or reduction of endoneurial edema, which results in improvementof nerve conduction function.
The adverse effects of IVIg are usually minor. Mild to moderate headache, chills, myalgia, nausea and fever can last for 24-48 hours (12) . A severe anaphylactic reaction is rare, but careful observation during and after administration is necessary. Acute renal tubular necrosis, often reversible, can occur with IVIg therapy in those who have pre-existing renal disease (15) . Our patient, who had renal failure and hypertension, received a reduced dose of IVIg (0.4 g/kg/day for three days) for fear of congestive heart failure, which was still sufficiently ef- fective. Strokes, myocardial infarction and pulmonary embolism have been reported in elderly or hypertensive patients ( 16, 17) . Our patient suffered from ischemic stroke, but it occurred 20 weeks after the therapy. So we believe that her stroke was not the complication of IVIg. In spite of the side effects mentionedabove and the unknown mechanism of IVIg therapy, the dramatic effect of IVIg on DA is worthy of special mention. This treatment will be very valuable for patients with DA.
